Research and Development
Atossa Genetics has a broad patent portfolio comprising numerous biomarkers with potential use in a variety of breast cancer diagnostic tests and services. We intend to use our expertise in NAF sample collection and breast cancer cell profiling to develop multiple products that may improve the detection and treatment of breast cancer and may provide important risk information that enables improved strategies for breast cancer prevention. All of our product development efforts are focused on reducing the impact of breast cancer through early detection and by enabling effective preventive measures.
Our current product development pipeline includes the FullCYTE Test, ArgusCYTE Test, and the NextCYTE Test. The FullCYTE Test is designed to gather information on the presence of normal, abnormal, or cancerous cells in each of the 5-7 milk ducts in the breast in women previously identified to be at high risk for breast cancer. The test is designed to identify precancerous changes in specific ducts, potentially enabling more targeted therapy than can be achieved with systemic therapies or current biopsy methods. The diagnostic analysis utilizes the same methods as our ForeCYTE Test.
The ArgusCYTE Test has been developed to improve the care of women already diagnosed with breast cancer. In clinical trials, the ArgusCYTE test has been able to detect circulating breast tumor cells (CTCs) in a small blood sample.1 Identifying CTCs before breast cancer spreads to other parts of the body can be important in making treatment decisions that can reduce the risk of metastasis. The ArgusCYTE Test is very sensitive and can detect as few as 10 CTCs in a 5 mL sample of blood.1 In addition to guiding breast cancer treatment, the ArgusCYTE Test may also have potential in monitoring disease recurrence in patients who have been treated successfully for breast cancer.
The NextCYTE Test is designed to help predict treatment outcomes and distant recurrence in women with newly diagnosed breast cancer. The test applies advanced genomic technologies to surgically-obtained breast tissue, providing critical insight into the activity of specific cancer-related pathways. We believe that data provided by the NextCYTE Test will enable more customized treatment options that target the genetic pathways of individual tumors.
1 Atossa Genetics, Inc., Data on File.